Building the Case for Clopidogrel as a World Health Organization Essential Medicine

被引：17

作者：

Patel, Amisha ^{[1
,2
]}

Vidula, Mahesh ^{[3
]}

Kishore, Sunny P. ^{[4
,5
]}

Vedanthan, Rajesh ^{[6
]}

Huffman, Mark D. ^{[1
,2
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA

[2] Northwestern Univ, Feinberg Sch Med, Dept Med Cardiol, Chicago, IL 60611 USA

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA

[5] Young Profess Chron Dis Network, Boston, MA USA

[6] Icahn Sch Med Mt Sinai, Dept Med Cardiol, New York, NY 10029 USA

来源：

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2015年 / 8卷 / 04期

基金：

美国国家卫生研究院;

关键词：

clopidogrel; drugs; essential; World Health Organization; PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION; TERM COST-EFFECTIVENESS; CARDIOVASCULAR-DISEASE; ANTIPLATELET THERAPY; MIDDLE-INCOME; MORTALITY; ASPIRIN; TRENDS; PRETREATMENT;

D O I：

10.1161/CIRCOUTCOMES.115.001866

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：447 / 451

页数：5

共 42 条

[1]

Amsterdam EA, 2014, CIRCULATION, V130, P2354, DOI 10.1161/CIR.0000000000000133

[2]

[Anonymous], INT DRUG PRIC IND GU

[3]

[Anonymous], WORLD EC OUTL DAT

[4] Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - Results from The Clopidogrel for the Reduction of Events During Observation (CREDO) trial [J].

Beinart, SC ;

Kolm, P ;

Veledar, E ;

Zhang, ZF ;

Mahoney, EM ;

Bouin, O ;

Gabriel, S ;

Jackson, J ;

Chen, R ;

Caro, J ;

Steinhubl, S ;

Topol, E ;

Weintraub, WS .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (05) :761-769

[5] Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention A Systematic Review and Meta-analysis [J].

Bellemain-Appaix, Anne ;

O'Connor, Stephen A. ;

Silvain, Johanne ;

Cucherat, Michel ;

Beygui, Farzin ;

Barthelemy, Olivier ;

Collet, Jean-Philippe ;

Jacq, Laurent ;

Bernasconi, Francois ;

Montalescot, Gilles .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (23) :2507-2516

[6] Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation:: A European model based on the CLARITY and COMMIT trials [J].

Berg, Jenny ;

Lindgren, Peter ;

Spiesser, Julie ;

Parry, David ;

Jonsson, Bengt .

CLINICAL THERAPEUTICS, 2007, 29 (06) :1184-1202

[7]

Bloom DE., 2012, The global economic burden of noncommunicable diseases

[8] Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events [J].

Bowry, Ashna D. K. ;

Brookhart, M. Alan ;

Choudhry, Niteesh K. .

AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (07) :960-966

[9]

Creager M A, 1998, Vasc Med, V3, P257, DOI 10.1191/135886398677811630

[10] DID PROGNOSIS AFTER ACUTE MYOCARDIAL-INFARCTION CHANGE DURING THE PAST 30 YEARS - A METAANALYSIS [J].

DEVREEDE, JJM ;

GORGELS, APM ;

VERSTRAATEN, GMP ;

VERMEER, F ;

DASSEN, WRM ;

WELLENS, HJJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (03) :698-706

← 1 2 3 4 5 →